Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
16.93
-0.36 (-2.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
February 28, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
February 26, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts
February 26, 2025
Via
Benzinga
Earnings Scheduled For February 25, 2025
February 25, 2025
Via
Benzinga
4 Analysts Have This To Say About Arcutis Biotherapeutics
February 10, 2025
Via
Benzinga
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
January 13, 2025
Via
Benzinga
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
August 28, 2024
Via
Benzinga
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
February 26, 2025
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.
Via
Stocktwits
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 25, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
February 24, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
February 06, 2025
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.
Via
Investor's Business Daily
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
January 13, 2025
Via
Benzinga
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
January 12, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
December 30, 2024
Via
Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
December 30, 2024
Via
Benzinga
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
December 16, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
November 13, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
October 24, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
October 22, 2024
Via
Benzinga
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
October 18, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
September 25, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
September 24, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
September 19, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
September 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
August 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
August 23, 2024
Via
Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
August 15, 2024
Via
Benzinga
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
August 14, 2024
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.